IBD and Crohn's in Canada — why waiting for a gastroenterologist is different when your disease is active

Most specialist waits in Canada are frustrating but, in a clinical sense, survivable — you wait, nothing much changes, you eventually get seen. Inflammatory bowel disease is not one of those. If you have Crohn's disease or ulcerative colitis and your disease is active, the months you spend in the gastroenterology queue are not neutral. Untreated inflammation is doing something the whole time: damaging the bowel wall, driving up the risk of strictures, fistulas, hospitalisation and surgery, and quietly narrowing your future options. This article explains why an IBD wait is a different kind of risk, how to tell whether your disease is genuinely active, what your GP can do in the meantime, and when the answer is not "wait" but "go now."

Why an IBD wait is not like other waits

The reason time matters in IBD comes down to a single idea that has reshaped how the disease is managed over the last decade: "treat to target." Modern gastroenterology no longer aims merely to make a patient feel better — it aims to switch off the underlying inflammation and heal the bowel lining, because ongoing inflammation, even when symptoms are mild, accumulates structural damage over time. Every flare that goes uncontrolled is a deposit into a bank of irreversible harm: scar tissue that narrows the bowel (strictures), abnormal tunnels between loops of bowel or to the skin (fistulas), and eventually the bowel resections that a large share of Crohn's patients undergo within years of diagnosis.

That is what makes the wait dangerous. A four- to nine-month delay for an orthopaedic opinion means four to nine months of the same knee. Four to nine months of untreated active Crohn's can mean a bowel that is measurably worse — and a treatment plan that now has to work harder, or a complication that could have been avoided. The window to control inflammation is real, and it closes.

Canada has among the highest prevalence of IBD in the world. Hundreds of thousands of Canadians live with Crohn's or ulcerative colitis, and incidence has been rising — including, notably, in populations where the disease was once rare. This is not a fringe condition being over-treated; it is a common, serious, lifelong disease competing for scarce specialist time.

What "active disease" actually looks like

The most important question in the whole waiting period is: is my disease active right now? Because a patient in genuine remission can, uncomfortably, afford to wait — while a patient with active inflammation cannot. Active disease is not just "feeling off." It has a recognisable clinical signature:

• Ongoing diarrhoea — loose, frequent stools that persist rather than settle
• Blood in the stool — visible bleeding or dark stools, a hallmark of active colitis
• Abdominal pain and cramping — often worse after eating, or localised in Crohn's
• Unintended weight loss — a sign the gut isn't absorbing, or that inflammation is driving a catabolic state
• Fatigue — profound and disproportionate, often driven by inflammation and iron-deficiency anaemia
• Raised inflammatory markers — a high faecal calprotectin (a stool test that measures bowel-wall inflammation directly) and a raised CRP in the blood

Faecal calprotectin deserves special emphasis, because it is the single most useful test a GP can order to answer the "active or not?" question objectively. Symptoms can mislead — irritable bowel can mimic a flare, and some Crohn's inflammation is quieter than the patient feels. Calprotectin cuts through that: a clearly raised level means the bowel is inflamed and needs specialist attention; a low level is reassuring. It is a cheap, non-invasive stool test, and far too few patients in the queue have had one.

The Canadian IBD pathway — and where the waits bite

The standard route looks simple on paper: GP → gastroenterology referral → colonoscopy/scope → therapy. In practice, the delay compounds at nearly every step.

• GP to gastroenterology referral: commonly 3 to 9 months for a non-urgent referral, depending on province and centre. The national median specialist wait was roughly 30 weeks from GP referral to treatment (Fraser Institute, Waiting Your Turn, 2024), with gastroenterology among the busier specialties.
• The scope: even once you're seen, a colonoscopy to confirm and stage the disease can add further weeks to months. Diagnosis often isn't made until the scope is done and biopsies are back.
• Starting and escalating therapy: getting onto — and then adjusting — the right drug (and increasingly, biologics) is itself a staged process. Each step that stalls is more time with active inflammation.

Add these together and a patient with a genuine flare can spend the better part of a year between "something is wrong" and "the inflammation is finally controlled." For active IBD, that is precisely the interval in which avoidable damage accrues. Province-specific gastroenterology wait times are worth knowing: see our detailed breakdowns for gastroenterologist wait times in BC and gastroenterologist wait times in Ontario.

When it's urgent — do not wait

Some IBD presentations are emergencies, and no queue applies to them. Seek urgent care or call 9-1-1 / go to the emergency department if you have any of the following:

• A severe flare — high stool frequency (many times a day) with significant rectal bleeding
• Signs of bowel obstruction — severe cramping abdominal pain, distension, persistent vomiting, and no passage of stool or gas
• Heavy or continuous rectal bleeding, or passing large clots
• Systemic symptoms — high fever, a racing heart, lightheadedness, or feeling profoundly unwell alongside gut symptoms, which can signal a severe flare or complication

These are not "wait for the specialist" situations. Acute severe colitis, in particular, is a recognised medical emergency that is managed in hospital. If your instinct says this is serious, act on it.

What your GP can do while you wait

Your GP cannot substitute for a gastroenterologist, but there is a great deal of useful, disease-relevant work they can do in the interim — and much of it is under-used.

Establish whether the disease is active. Bloods for a full blood count (CBC), ferritin and iron studies, and CRP, plus a faecal calprotectin, give an objective read on inflammation and on complications like iron-deficiency anaemia. This is the single most valuable thing a GP can order.

Rule out infection masquerading as a flare. Stool cultures — including C. difficile — matter, because a gut infection can look exactly like an IBD flare, and the treatment is completely different. Steroids or immunosuppression given to someone who actually has an infection can do harm.

Check that current therapy is actually controlling the disease. This is where a lot of quiet damage hides. A patient who is still flaring on their current medication may simply be on inadequate treatment. A common and important example: mesalazine (5-ASA) has limited evidence of benefit in Crohn's disease — it is a mainstay in ulcerative colitis but is often continued in Crohn's patients who are not actually being helped by it. If you have Crohn's and remain symptomatic on mesalazine, that is a red flag worth escalating. We cover this specific problem in depth in our companion article on what to do when mesalazine isn't working for Crohn's.

The point of all this is not to have your GP manage the IBD alone — it's to make sure that when your specialist appointment finally arrives, the workup is done, infection is excluded, and any inadequate therapy has already been flagged, so the visit moves straight to a decision.

The NRI and South Asian angle

There's a demographic dimension to this that matters for a large part of the community Ginie Health serves. IBD was historically considered rare in South Asians, but incidence has been rising sharply among South Asians in Western countries, including Canada — and often presents in younger patients. Migration, diet, and environment appear to unmask a susceptibility that was always there. The upshot is that a growing number of South Asian Canadians are being diagnosed with Crohn's and ulcerative colitis, frequently without the family history or cultural familiarity that would prompt early action.

There is also a real depth of expertise on the other side of this. Indian tertiary centres such as PGIMER Chandigarh and AIIMS run high-volume IBD services and have substantial experience with exactly this disease in exactly this population — including the tricky overlap with intestinal tuberculosis, which can mimic Crohn's and which Western gastroenterologists see far less often. For an NRI patient navigating a Canadian wait, a gastroenterologist trained in that environment offers a particularly relevant second opinion.

How a specialist opinion from Ginie Health works for IBD patients

Here is the service in plain terms for your situation — a Canadian patient with active or suspected IBD, facing months in the gastroenterology queue. You upload your results (bloods, calprotectin, any prior scope reports) and describe your symptoms and current medications. Within 6 hours, for $45 CAD, you receive a written clinical opinion from a gastroenterologist trained at PGIMER Chandigarh or AIIMS — centres with major IBD expertise and high patient volumes.

The opinion tells you whether your disease looks active, whether your current therapy is adequate (or whether, for example, you're a Crohn's patient stuck on mesalazine that isn't working), which additional tests to push for, and exactly what to raise with your GP or at your gastroenterology appointment when it arrives. It does not replace that appointment or your scope — it makes the waiting time count, and it catches inadequate treatment before more damage is done. If you'd rather talk it through, a live video consultation is available for $75 CAD. No referral required for either. And to be absolutely clear: if you are in a severe flare, obstructed, or bleeding heavily, this is not the route — that is urgent care or 9-1-1.